Quality of life and guidelines for PSA screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.Journal of the National Cancer Institute · 2015
   Trial
2. Simultaneous Thoracic Spine Metastatic Melanoma and Pre-existing Prostate Adenocarcinoma: A Unique Case Presentation and Literature Review.Cureus · 2023
   Article
3. The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer.BioMed research international · 2020
   Article
4. Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer.Medicine · 2019
   Article
5. A Patient-Centered Approach to Comparative Effectiveness Research Focused on Older Adults: Lessons From the Patient-Centered Outcomes Research Institute.Journal of the American Geriatrics Society · 2019
   Article
6. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2018
   Article
7. Prostate Cancer Screening.The Medical clinics of North America · 2018
   Review
8. A Framework for Treatment Decision Making at Prostate Cancer Recurrence.Medical decision making : an international journal of the Society for Medical Decision Making · 2017
   Article
9. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.JAMA oncology · 2016
   Article
10. Comparative Effectiveness Research: A Roadmap for Physical Activity and Lifestyle.Medicine and science in sports and exercise · 2015
    Article
11. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN.Methods (San Diego, Calif.) · 2015
    Review
12. What do the screening trials really tell us and where do we go from here?The Urologic clinics of North America · 2014
    Review
13. Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).Prostate cancer and prostatic diseases · 2014
    Article
14. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2013
    Article
15. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Annals of internal medicine · 2013
    Article
16. Do clinical guidelines still make sense? Yes.Annals of family medicine
    Article

Corrections and comments

• Comment on
  Quality-of-life effects of prostate-specific antigen screening.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as